(Sivaprasad and Chong, 2006) The complement system targeting inhibitors, such as Zimura, a polyethylene glycol (PEG), chemically synthesized single-stranded nucleic acid aptamer targeting complement factor C5 and pegcetacoplan, a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) that specifically target C3 and C3b have shown capacity to decrease geographic atrophy (GA) growth without adverse events in participants with GA secondary to AMD when administered subcutaneously. This evidence concerns the gene C3 and atrophic macular degeneration.